FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > New BRCA Genetic Screening Recommendations Miss the Mark


11/1/2019 - FORCE, along with hundreds of medical and patient advocacy orgs, expressed support for a long-term reauthorization of PCORI.

10/28/2019 - We authored comments on the FDA's draft industry guidance on developing drugs for the treatment of male breast cancer.

9/27/2019 - FORCE and two dozen groups urged CMS to reconsider the 14-day Rule, which has created delays in patients receiving test results.

9/24/2019 - Signed onto a letter urging the President to waive out-of-pocket costs for seniors on Medicare who have precancerous polyps removed during a screening colonoscopy.

9/3/2019 - We joined over 50 orgs representing patients, advocates, caregivers, researchers, and physicians to support the appointment of Norman Sharpless as FDA Commissioner.

New BRCA Genetic Screening Recommendations Miss the Mark

Genetic Testing & Counseling


September 2019 - Recommendations published by the U.S. Preventive Services Task Force (USPSTF) guide the use of many health screenings and determine which preventive services are available at no cost-sharing under the Affordable Care Act (ACA). Typically reviewed and updated every 5 years, the Task Force recently published new guidelines that slightly expand the population eligible for BRCA counseling and testing by adding women “who have an ancestry associated with BRCA1/2 gene mutations.” While this change is positive, the guidelines are significantly lacking and fall short of meeting the needs of Americans who may be at increased risk of cancer due to hereditary factors. 

The updated guidelines state that the patient population under consideration includes “women who have never been diagnosed with BRCA-related cancer, as well as those with a previous breast, ovarian, tubal, or peritoneal cancer diagnosis who have completed treatment and are considered cancer free but have not been previously tested.” Contrary to what some have claimed, inclusion of women with a prior cancer diagnosis is not new. The 2013 guidelines stated that the recommendation “applies to asymptomatic women who have not been diagnosed with BRCA-related cancer.” After ongoing discussions with FORCE about the need to include survivors, federal agencies issued this clarification (see highlighted text, pages 2-3) in 2015. Similarly, the Department of Labor published an interpretation indicating that the guidelines also applied to women previously diagnosed with cancer, “as long as she is not currently symptomatic of or receiving active treatment for breast, ovarian, tubal, or peritoneal cancer.”

Earlier this year, the Task Force invited public comments on new draft guidelines for "BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing.”  In our opinion, the proposed guidelines did not adequately represent the wide-ranging needs of the hereditary cancer community. FORCE, joined by over a dozen other patient advocacy organizations, submitted a comprehensive response advocating for more current and inclusive recommendations. Unfortunately, the Task Force did not incorporate most of these suggestions.

Included Populations
Ultimately, the new guidelines fail to include key populations including men, women with a personal or family history of cancers other than breast or ovarian, and patients currently undergoing treatment. There is a relationship between inherited mutations such as BRCA and cancers beyond breast and ovarian, including prostate, pancreatic, male breast, and others. A substantial portion of people with mutations that increase their risk of cancer are missed with the narrow definition of the population under consideration.

Mutations Beyond BRCA
The recommendations neglect to acknowledge that multigene panels are now the standard-of-care in cancer genetic testing. Mutations in genes including but not limited to ATM, CDH1, CHEK2, MLH1, MSH2, PALB2, PTEN, TP53 and STK11 increase the risk of breast and/or ovarian as well as other cancers. Multiple studies demonstrate that compared with multigene next-generation sequencing (NGS) panels, BRCA1/2 testing alone misses potentially actionable findings in a substantial proportion of cases. 

Screenings & Interventions
Rather than give letter grades to the preventive screenings and risk-reducing surgeries needed after a person learns that they carry a mutation, the Task Force simply outlines the options. This leads to insurance coverage gaps for genetic testing and related services such as mammograms before age 40, breast screening MRIs, and risk-reducing surgeries. FORCE advocates that these interventions constitute “prevention” and should receive letter grades from the USPSTF in order to facilitate affordable access. Without letter grades from the Task Force, insurers are not required to cover the vast majority of services needed by those at high risk of cancer. Many people incur large out-of-pocket expenses on an annual basis as a result.


The U.S. Preventive Services Task Force is an independent panel of national experts that makes evidence-based recommendations about preventive health services such as screenings, counseling services, and preventive medications. The Task Force publishes guidelines on screenings such as breast mammograms, colonoscopies, and PSA testing for prostate cancer. Any screening receiving a grade "A" or "B" is covered as an essential preventive service under the Affordable Care Act (ACA). These services must be provided at no cost under the ACA. Health insurers often look to the USPSTF to determine what preventive services to cover. As such, gaps in the Task Force guidelines often affect access to health care. For more information on this, see our article entitled, "High-Risk Individuals Often Struggle to Get Insurance Coverage of Health Services."


Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered